share_log

中國生物製藥：截至二零二四年三月三十一日止月份的股份發行人的證券變動月報表

SINO BIOPHARM: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024

香港交易所 ·  Apr 2 09:56
Summary by Futu AI
中國生物製藥有限公司於2024年4月2日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的公司股本變動情況。報告顯示，公司的法定/註冊股本及已發行股份在本月內均無變動，法定/註冊股本總額維持在750,000,000港元，而已發行股份結存為18,801,217,230股。此外，公司在2023年6月15日股東週年大會上獲採納的股份期權計劃本月內無變動，且無新股份因行使期權而發行。報告還提到，公司的零息可轉換債券將於2025年到期，但本月內亦無變動，且無新股份因轉換債券而發行。公司確認所有證券發行均已獲得董事會授權，並符合香港聯合交易所有限公司證券上市規則的要求。
中國生物製藥有限公司於2024年4月2日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的公司股本變動情況。報告顯示，公司的法定/註冊股本及已發行股份在本月內均無變動，法定/註冊股本總額維持在750,000,000港元，而已發行股份結存為18,801,217,230股。此外，公司在2023年6月15日股東週年大會上獲採納的股份期權計劃本月內無變動，且無新股份因行使期權而發行。報告還提到，公司的零息可轉換債券將於2025年到期，但本月內亦無變動，且無新股份因轉換債券而發行。公司確認所有證券發行均已獲得董事會授權，並符合香港聯合交易所有限公司證券上市規則的要求。
China Biopharmaceuticals Limited filed with Hong Kong Trading and Settlement Limited on 2 April 2024 with Hong Kong Trading and Settlement Limited, reporting the changes in the company's share capital as of 31 March 2024. THE REPORT SHOWS THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL AND ISSUED SHARES REMAINED UNCHANGED DURING THE MONTH. THE TOTAL STATUTED/REGISTERED SHARE CAPITAL REMAINED AT HK$750,000,000 AND THE ISSUED SHARES WERE DEPOSITED AT 18,801,217,230 SHARES. In addition, the share option plan adopted by the Company at its Annual General Meeting on June 15, 2023 was unchanged during the month and no new shares were issued as a result of the exercise of the options. The report also noted that the company's zero-yield convertible bonds will mature in 2025, but were unchanged this month and no new shares were issued as a result of the convertible bonds. The Company confirms that all issuance of securities has been authorised by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
China Biopharmaceuticals Limited filed with Hong Kong Trading and Settlement Limited on 2 April 2024 with Hong Kong Trading and Settlement Limited, reporting the changes in the company's share capital as of 31 March 2024. THE REPORT SHOWS THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL AND ISSUED SHARES REMAINED UNCHANGED DURING THE MONTH. THE TOTAL STATUTED/REGISTERED SHARE CAPITAL REMAINED AT HK$750,000,000 AND THE ISSUED SHARES WERE DEPOSITED AT 18,801,217,230 SHARES. In addition, the share option plan adopted by the Company at its Annual General Meeting on June 15, 2023 was unchanged during the month and no new shares were issued as a result of the exercise of the options. The report also noted that the company's zero-yield convertible bonds will mature in 2025, but were unchanged this month and no new shares were issued as a result of the convertible bonds. The Company confirms that all issuance of securities has been authorised by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.